BayWa's Fate Hinges on Creditor Talks and Asset Sale

German trader BayWa faces a critical deadline to secure bank support for its restructuring, relying on asset sales like T&G Global while grappling with governance issues and a collapsed energy deal.

The clock is ticking for German agricultural trader BayWa. While the company has made progress by reducing debt by €1.3 billion through asset sales, including the completed Cefetra divestment, this represents barely a third of its ultimate €4 billion deleveraging target. A critical €45 million payment from that Cefetra deal is due by the end of April, supplemented by roughly €62 million from shareholder loan repayments. For a company in BayWa's position, these cash infusions are vital currency in ongoing negotiations with its core lenders.

Those negotiations are the linchpin of the entire restructuring effort. Management is seeking an extension of its standstill agreement with key banks DZ Bank and HVB until autumn 2026. Securing this breathing room is essential for executing the next major portfolio move: the sale of its nearly 74% stake in New Zealand fruit company T&G Global. Analysts estimate this sale could yield around €300 million. Should the banks refuse, the foundation of the entire rescue plan would collapse.

However, the T&G sale itself faces a specific complication. Hong Kong's Joy Wing Mau Group holds a minority stake of nearly 20%, which could potentially complicate the sales process in New Zealand. This planned divestment has taken on heightened importance after the collapse of a cornerstone restructuring deal earlier this year. The original plan to sell a 51% stake in renewable energy unit BayWa r.e. for up to €1.7 billion fell apart after U.S. renewable energy subsidies were cut in early 2025, causing the potential sale price to plummet.

The uncertainty surrounding this massive corporate overhaul is palpable in the markets. BayWa's shares have shed approximately 21% since the start of the year and recently traded more than 23% below their 200-day moving average. In a single session this Wednesday, the stock fell 4.83% to €13.80.

Beyond the balance sheet, structural governance issues are adding to investor unease. BayWa is changing its auditor following a rebuke from German financial watchdog BaFin. The regulator criticized the company's 2023 annual report for omitting details on a billion-euro loan and refinancing risks linked to a €500 million bond. The auditor oversight body Apas has initiated proceedings. PwC is auditing the 2025 accounts for the final time, with the certified financial statement not expected until the fourth quarter of 2026. This creates a months-long valuation gap, making a reliable fundamental assessment of the equity nearly impossible for investors in the interim.

Operationally, the restructuring follows a clear roadmap. By the end of 2028, BayWa aims to be concentrated on four core business areas. The plan involves cutting approximately 1,300 jobs, permanently closing 26 branches, and reducing group revenue to around €10 billion. The adjusted EBITDA target for 2027 is roughly €140 million. Internally, the supervisory board has slashed the approval threshold for business deals from €200 million to €50 million, a direct response to past control failures. The company has already withdrawn its financial forecast for 2026.

The imminent Cefetra payment is the next measurable milestone. Yet the ultimate success of the transformation depends on two intertwined outcomes: the goodwill of its banks and the ability to successfully offload T&G Global despite the complicating minority shareholder.